EICHOR
● Not Yet Recruiting
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Condition: HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases · Sponsor: Sun Yat-sen University
About this study
This study aims to evaluate the efficacy and safety of adding the anti-angiogenic agent anlotinib to the combination of the CDK2/4/6 inhibitor Culmerciclib and endocrine therapy in patients with HR+/HER2- breast cancer and brain metastases. Eligible patients present with newly diagnosed brain metastases or brain metastases that progressed following prior local therapy. It is hoped that this therapeutic combination can achieve disease control in these patients.
This description comes directly from the study's public registry record.
Talk to the study team
Shusen Wang, MD · +8613926168469 · wangshs@sysucc.org.cn
Always discuss trial participation with your own doctor first.
Locations (9)
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | — |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | — |
| Anyang Tumor Hospital | Anyang, Henan, China | — |
| Henan Cancer Hospital | Zhengzhou, Henan, China | — |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | — |
| Nanchang People's Hospital | Nanchang, Jiangxi, China | — |
| The Second Affiliated Hospital of Dalian Medical University | Dalian, Liaoning, China | — |
| Sichuan Provincial People's Hospital | Chengdu, Sichuan, China | — |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07745257